Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Sandra Irvine"'
Autor:
Amjad Hayat, Shaun R. McCann, Stephen Langabeer, Sandra Irvine, Mary Frances McMullin, Eibhlin Conneally
Publikováno v:
Haematologica, Vol 94, Iss 2 (2009)
Externí odkaz:
https://doaj.org/article/2cecfd24fd4c4b46a83cdd42d84fbf7b
Autor:
Kai-Keen Shiu, Jenny F. Seligmann, Janet Graham, Richard H. Wilson, Mark P. Saunders, Timothy Iveson, Hamzeh Kayhanian, Khurum H. Khan, Manuel Rodriguez-Justo, Marnix Jansen, Austin Obichere, Andrew Plumb, Edward Seward, Sandra Irvine, William Wilson, Reshma Bhat, Sharon Forsyth, Laura White
Publikováno v:
Journal of Clinical Oncology. 40:TPS3645-TPS3645
TPS3645 Background: The prognostic advantage of early stage deficient-MMR/MSI-High CRC is lost after relapse, so there is a pressing clinical need to maximize the chance of cure in the early stages where prevalence of dMMR is higher comprising approx
The 6th International Workshop of the CCN Family of Genes was held from October 20th–24th 2010, at the grand, picturesque location of the Slieve Donard Hotel, in Newcastle, Northern Ireland, and was efficiently hosted by Dr Sandra Irvine on behalf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8f2c053afe5770b1bdfda3110facb0e
https://europepmc.org/articles/PMC3058189/
https://europepmc.org/articles/PMC3058189/
Autor:
Sandra Irvine, Eibhlin Conneally, Mary Frances McMullin, Amjad Hayat, Stephen E. Langabeer, Shaun R. McCann
Despite recent advances in the treatment of chronic myeloid leukemia (CML), allogeneic stem-cell transplantation (SCT) remains the only curative option. The success of SCT is limited because of relapse in 20–30% of patients.1,2 As the graft-versus-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1febba589d99aaa93669bbe6606fd103
http://hdl.handle.net/2262/34395
http://hdl.handle.net/2262/34395
Publikováno v:
Queen's University Belfast-PURE
CML is a disease of the haemopoietic stem cell (HSC) caused by the constitutively active tyrosine kinase Bcr-Abl. The current first-line therapy for CML is imatinib (IM), a tyrosine kinase inhibitor (TKI) effective in establishing durable disease con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a96b7189f1c09b75222e6b606e05eeb4
https://pure.qub.ac.uk/en/publications/2e5237ac-3666-4336-89c8-eed894898cc5
https://pure.qub.ac.uk/en/publications/2e5237ac-3666-4336-89c8-eed894898cc5